ロード中...
Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism
Targeting Bruton's tyrosine kinase (BTK) with the small molecule BTK inhibitor ibrutinib has significantly improved patient outcomes in several B-cell malignancies, with minimal toxicity. Given the reported expression and constitutive activation of BTK in acute myeloid leukemia (AML) cells, the...
保存先:
| 出版年: | Oncotarget |
|---|---|
| 主要な著者: | , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Impact Journals LLC
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4823070/ https://ncbi.nlm.nih.gov/pubmed/26624983 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6409 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|